135 related articles for article (PubMed ID: 28281196)
1. Pharmacokinetics of the Inhaled Selective Glucocorticoid Receptor Modulator AZD5423 Following Inhalation Using Different Devices.
Melin J; Prothon S; Kloft C; Cleton A; Amilon C; Jorup C; Bäckman P; Olsson B; Hamrén UW
AAPS J; 2017 May; 19(3):865-874. PubMed ID: 28281196
[TBL] [Abstract][Full Text] [Related]
2. Predicting Exposure After Oral Inhalation of the Selective Glucocorticoid Receptor Modulator, AZD5423, Based on Dose, Deposition Pattern, and Mechanistic Modeling of Pulmonary Disposition.
Bäckman P; Tehler U; Olsson B
J Aerosol Med Pulm Drug Deliv; 2017 Apr; 30(2):108-117. PubMed ID: 27740878
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Tolerability of an Inhaled Selective Glucocorticoid Receptor Modulator - AZD5423 - in Chronic Obstructive Pulmonary Disease Patients: Phase II Study Results.
Kuna P; Aurivillius M; Jorup C; Prothon S; Taib Z; Edsbäcker S
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):279-289. PubMed ID: 28212463
[TBL] [Abstract][Full Text] [Related]
4. Safety, Pharmacokinetics and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator AZD5423 after Inhalation in Healthy Volunteers.
Werkström V; Prothon S; Ekholm E; Jorup C; Edsbäcker S
Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):574-581. PubMed ID: 27214145
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary Dissolution of Poorly Soluble Compounds Studied in an ex Vivo Rat Lung Model.
Eriksson J; Thörn H; Sjögren E; Holmstén L; Rubin K; Lennernäs H
Mol Pharm; 2019 Jul; 16(7):3053-3064. PubMed ID: 31136181
[TBL] [Abstract][Full Text] [Related]
6. On the pharmacokinetics of two inhaled budesonide/formoterol combinations in asthma patients using modeling approaches.
Soulele K; Macheras P; Karalis V
Pulm Pharmacol Ther; 2018 Feb; 48():168-178. PubMed ID: 29223508
[TBL] [Abstract][Full Text] [Related]
7. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study.
Azouz W; Chetcuti P; Hosker H; Saralaya D; Chrystyn H
BMC Pulm Med; 2015 May; 15():47. PubMed ID: 25927483
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of fluticasone propionate multidose, inhalation-driven, novel, dry powder inhaler versus a prevailing dry powder inhaler and a metered-dose inhaler.
Gillespie M; Song S; Steinfeld J
Allergy Asthma Proc; 2015; 36(5):365-71. PubMed ID: 26314817
[TBL] [Abstract][Full Text] [Related]
9. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
[TBL] [Abstract][Full Text] [Related]
10. Assessment of satisfaction with different dry powder inhalation devices in Greek patients with COPD and asthma: the ANASA study.
Zervas E; Samitas K; Gaga M
Int J Chron Obstruct Pulmon Dis; 2016; 11():1845-55. PubMed ID: 27540287
[TBL] [Abstract][Full Text] [Related]
11. Usage and usability of one dry powder inhaler compared to other inhalers at therapy start: an open, non-interventional observational study in Poland and Germany.
Hantulik P; Wittig K; Henschel Y; Ochse J; Vahteristo M; Rytila P
Pneumonol Alergol Pol; 2015; 83(5):365-77. PubMed ID: 26378998
[TBL] [Abstract][Full Text] [Related]
12. [New dry powder inhalers].
Emeryk A; Pirożyński M
Pneumonol Alergol Pol; 2015; 83(1):83-7. PubMed ID: 25577539
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a 12-week therapy with a new formulation of fluticasone propionate at doses of 125 and 250 μg administered through a new generation cyclohaler twice daily, in comparison to fluticasone propionate 500 μg dry powder inhaler twice daily in patients with moderate asthma.
Kupryś-Lipińska I; Tworek D; Vanderbist F; Bocheńska-Marciniak M; Kuna P
Pneumonol Alergol Pol; 2013; 81(6):527-36. PubMed ID: 24142782
[TBL] [Abstract][Full Text] [Related]
14. Prospective evAluatIon foR inhalation devices in Greek patients with COPD and asthma: The PAIR study.
Karampitsakos T; Hillas G; Zervas E; Bakakos P; Stratakos G; Dimakou K; Manali E; Bouros D; Papiris S; Tzouvelekis A;
Pulm Pharmacol Ther; 2020 Feb; 60():101882. PubMed ID: 31881275
[TBL] [Abstract][Full Text] [Related]
15. Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation.
Borghardt JM; Weber B; Staab A; Kunz C; Kloft C
Br J Clin Pharmacol; 2016 Sep; 82(3):739-53. PubMed ID: 27145733
[TBL] [Abstract][Full Text] [Related]
16. Equivalent Lung Dose and Systemic Exposure of Budesonide/Formoterol Combination via Easyhaler and Turbuhaler.
Lähelmä S; Sairanen U; Haikarainen J; Korhonen J; Vahteristo M; Fuhr R; Kirjavainen M
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):462-73. PubMed ID: 25757188
[TBL] [Abstract][Full Text] [Related]
17. Numerical simulation of emitted particle characteristics and airway deposition distribution of Symbicort(®) Turbuhaler(®) dry powder fixed combination aerosol drug.
Farkas Á; Jókay Á; Balásházy I; Füri P; Müller V; Tomisa G; Horváth A
Eur J Pharm Sci; 2016 Oct; 93():371-9. PubMed ID: 27552906
[TBL] [Abstract][Full Text] [Related]
18. The inhalation characteristics of patients when they use different dry powder inhalers.
Azouz W; Chetcuti P; Hosker HS; Saralaya D; Stephenson J; Chrystyn H
J Aerosol Med Pulm Drug Deliv; 2015 Feb; 28(1):35-42. PubMed ID: 24815999
[TBL] [Abstract][Full Text] [Related]
19. Central and peripheral lung deposition of fluticasone propionate dry powder inhaler formulations in humans characterized by population pharmacokinetics.
Drescher SK; Jiao Y; Chen MJ; Kurumaddali A; Shao J; Amini E; Hochhaus G; Bulitta JB
Pharm Res; 2023 May; 40(5):1177-1191. PubMed ID: 37081302
[TBL] [Abstract][Full Text] [Related]
20. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler.
Pitcairn G; Reader S; Pavia D; Newman S
J Aerosol Med; 2005; 18(3):264-72. PubMed ID: 16181001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
